Caris Life Sciences, Inc.
CAI
$18.42
-$0.06-0.30%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 812.03M | 649.06M | 533.85M | 452.50M | 412.26M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 812.03M | 649.06M | 533.85M | 452.50M | 412.26M |
| Cost of Revenue | 270.99M | 258.46M | 246.34M | 241.12M | 231.83M |
| Gross Profit | 541.04M | 390.60M | 287.51M | 211.38M | 180.43M |
| SG&A Expenses | 396.37M | 376.52M | 360.89M | 334.04M | 326.05M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 766.92M | 729.41M | 707.68M | 675.35M | 669.39M |
| Operating Income | 45.11M | -80.34M | -173.83M | -222.85M | -257.12M |
| Income Before Tax | -68.09M | -186.99M | -279.05M | -273.44M | -281.89M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -68.09 | -186.99 | -279.05 | -273.44 | -281.89 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -68.09M | -186.99M | -279.05M | -273.44M | -281.89M |
| EBIT | 45.11M | -80.34M | -173.83M | -222.85M | -257.12M |
| EBITDA | 67.73M | -52.95M | -140.78M | -184.60M | -208.21M |
| EPS Basic | -11.16 | -13.18 | -15.86 | -10.43 | -10.67 |
| Normalized Basic EPS | -2.08 | -2.91 | -4.15 | -4.80 | -4.97 |
| EPS Diluted | -11.17 | -13.19 | -15.87 | -10.44 | -10.67 |
| Normalized Diluted EPS | -2.09 | -2.91 | -4.15 | -4.80 | -4.97 |
| Average Basic Shares Outstanding | 664.86M | 418.30M | 171.84M | 142.30M | 141.99M |
| Average Diluted Shares Outstanding | 693.84M | 433.41M | 171.84M | 142.30M | 141.99M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |